A Meta-analysis of carbon ion radiotherapy for stage Ⅰ non-small cell lung cancer
10.3760/cma.j.issn.0254-5098.2016.08.008
- VernacularTitle:碳离子治疗Ⅰ期非小细胞肺癌的Meta分析
- Author:
Qiuning ZHANG
;
Jinhui TIAN
;
Qianru LI
;
Ruifeng LIU
;
Hong ZHANG
;
Yan YANG
;
Xiaohu WANG
- Publication Type:Journal Article
- Keywords:
Carbon ion;
Non-small cell lung cancer;
Meta-analysis
- From:
Chinese Journal of Radiological Medicine and Protection
2016;36(8):594-600
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of the carbon ion radiotherapy for stage Ⅰ non-small cell lung cancer (NSCLC).Methods We searched multiple electronic bibliographic databases,including the Cochrane library,PubMed,EMBASE,China Journal Full-text Database,Chinese Biomedical Database,and the Wanfang Database to assemble the available studies of carbon ion radiotherapy for stage Ⅰ non-small cell lung cancer.MetaAnalyst Beta 3.13 and STATA 12.0 software were used to combine the extracted data.Results Ten studies (seven trials) were included.The overall survival rates of 1,3 and 5 years were 95.1％,68.5％ and 45.9％,respectively.The local control rates of 1,3 and 5 years were 90.2％,76.7％ and 81.2％,respectively.The cause specific survival rate of 1,3 and 5 years were 82.9％,58.5％ and 57.3％,respectively.The rate of primary recurrence and total recurrence were 45.8％ and 11％,respectively.The rates of total death and death from lung cancer were 52.4％ and 28.3％,respectively.There were differences observed between T1 stage and T2 stage in regards to five year overall survival rate,total recurrence,lung cancer death,and grade 1 and grade 2 skin toxicities.Conclusions Available data demonstrate that carbon ion radiotherapy,in general,is a safe and feasible treatment modality for stage Ⅰ NSCLC.Although current results are promising,more evidence is required before carbon ion radiotherapy can become the international standard treatment for lung cancer patients.
